293 related articles for article (PubMed ID: 11353655)
1. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
Barry AL; Fuchs PC; Brown SD
Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
[TBL] [Abstract][Full Text] [Related]
4. [In vitro evaluation of lomefloxacin].
Dette GA; Knothe H
Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
[TBL] [Abstract][Full Text] [Related]
5. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
[TBL] [Abstract][Full Text] [Related]
6. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
Ismaeel NA; Tayeb OS
Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
8. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
Moros M; Coll R; Esteve M; Parés J; Xicota MA
Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
[No Abstract] [Full Text] [Related]
10. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
11. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H
Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
Montanari MP; Mingoia M; Varaldo PE
Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
[TBL] [Abstract][Full Text] [Related]
14. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
15. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
Beskid G; Prosser BL
Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
[TBL] [Abstract][Full Text] [Related]
16. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
19. [In vitro activity of trovafloxacin, of other fluoroquinolones and of related antimicrobials against clinical isolates. Grupo colaborativo WHONET-Argentina].
Rossi A; Galas M; Tokumoto M; Guelfand L; Lopardo H
Medicina (B Aires); 1999; 59 Suppl 1():8-16. PubMed ID: 10436549
[TBL] [Abstract][Full Text] [Related]
20. Activity of 4-quinolones against Pseudomonas aeruginosa.
Morissey I; Smith JT
Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
